40/0mg taken first + 80/0mg taken first + 40/240mg taken first + 80/480mg taken first + 0/0mg taken first
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Opioid Abuse
Conditions
Opioid Abuse
Trial Timeline
Jan 1, 2010 → Feb 1, 2010
NCT ID
NCT01030406About 40/0mg taken first + 80/0mg taken first + 40/240mg taken first + 80/480mg taken first + 0/0mg taken first
40/0mg taken first + 80/0mg taken first + 40/240mg taken first + 80/480mg taken first + 0/0mg taken first is a phase 2 stage product being developed by Pfizer for Opioid Abuse. The current trial status is completed. This product is registered under clinical trial identifier NCT01030406. Target conditions include Opioid Abuse.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01030406 | Phase 2 | Completed |
Competing Products
20 competing products in Opioid Abuse
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| SUBLOCADE | Indivior PLC | Phase 3 | 72 |
| SUBLOCADE | Indivior PLC | Phase 3 | 72 |
| ASP8082 + morphine + Placebo | Astellas Pharma | Phase 1 | 33 |
| ASP8062 + Placebo ASP8062 + buprenorphine/naloxone | Astellas Pharma | Phase 1 | 33 |
| ASP8062 + Placebo ASP8062 + buprenorphine/naloxone | Astellas Pharma | Phase 2 | 52 |
| Naldemedine + Placebo | Shionogi | Phase 3 | 77 |
| Naldemedine + Placebo | Shionogi | Approved | 85 |
| Naldemedine | Shionogi | Phase 1/2 | 41 |
| Naldemedine + Placebo | Shionogi | Phase 3 | 77 |
| Placebo + Naldemedine | Shionogi | Phase 2 | 52 |
| Naldemedine + Placebo | Shionogi | Phase 3 | 77 |
| Naldemedine + Placebo | Shionogi | Phase 2 | 52 |
| Naloxegol | Kyowa Kirin | Pre-clinical | 23 |
| naloxegol + non-PAMORA laxative | Kyowa Kirin | Pre-clinical | 23 |
| Naloxegol | Kyowa Kirin | Pre-clinical | 23 |
| Naloxegol | Kyowa Kirin | Pre-clinical | 23 |
| Brenipatide + Placebo + Buprenorphine | Eli Lilly | Phase 2 | 52 |
| NKTR-118 + NKTR-118 + Placebo | AstraZeneca | Phase 3 | 77 |
| Naloxegol + Naloxegol | AstraZeneca | Phase 1 | 33 |
| NKTR-118 + Usual care | AstraZeneca | Phase 3 | 77 |